Hearticellgram-AMI (Autologous bone marrow derived mesenchymal stem cells)
/ Pharmicell
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 10, 2026
RELIEF: To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
(clinicaltrials.gov)
- P3 | N=90 | Completed | Sponsor: Pharmicell Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Myocardial Infarction
April 12, 2024
RELIEF: To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
(clinicaltrials.gov)
- P3 | N=90 | Active, not recruiting | Sponsor: Pharmicell Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2023 ➔ Oct 2024 | Trial primary completion date: Aug 2022 ➔ Oct 2024
Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction
1 to 2
Of
2
Go to page
1